Op-Ed: “Most Favored Nation” Drug Pricing Hurts Patients, Innovation, and New Jersey Jobs

By Chrissy Buteas, President and CEO, HealthCare Institute of New Jersey (HINJ – www.hinj.org) and

Dan Leonard, Executive Director, We Work For Health (WWFH – www.weworkforhealth.org)

April 29, 2026 | tapinto.net

Making medicines more affordable is a goal we all share. Patients, employers, innovators, and policymakers recognize that high costs can stand between patients and the care they need. But not every policy that promises lower prices delivers better outcomes. If policymakers were to codify a “most favored nation” (MFN) drug pricing policy – which would tie U.S. prices to those set by foreign governments – it would come at an extraordinary cost to patients, America’s scientific leadership, and New Jersey jobs. 

Read More: Click Here